- Home
- VSTD vs ADIL Comparison
VSTD vs ADIL Comparison
Compare VSTD & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTD | ADIL |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | 259 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 6.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | VSTD | ADIL |
|---|---|---|
| Price | $0.21 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 54.9K | ★ 95.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.13 |
| 52 Week High | $2.20 | $5.17 |
Technical Indicators
Market Signals| Indicator | VSTD | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 36.93 | 52.98 |
| Support Level | $0.21 | $1.59 |
| Resistance Level | $0.35 | $2.98 |
| Average True Range (ATR) | 0.02 | 0.21 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 13.93 | 55.82 |
Price Performance
Historical ComparisonAbout VSTD Vestand Inc.
Vestand Inc is a California-based fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.